Third Consecutive Win! Caremo Honored as One of the "2024-2025 Top 50 Pharmaceutical R&D Enterprises"!

November 10, 2025 – The 4th Tai Shan Medical Forum and the 2024-2025 Pharmaceutical Industry Information Release Conference, jointly organized by the Tai Shan Medical Forum Committee and 13 industry leaders including Yangtze River Pharmaceutical Group and Xiuzheng Pharmaceutical Group, successfully concluded in Jinan, Shandong.

During the conference, 11 statistical reports on the pharmaceutical industry for 2024-2025 were released. Caremo was recognized for its solid R&D strength and outstanding innovative achievements, earning a place among the "2024-2025 Top 50 Pharmaceutical R&D Enterprises." This marks the third consecutive year the company has received this honor.

The Pharmaceutical Industry Information Statistical Reports are compiled by the All-China Federation of Industry & Commerce - Chamber of Commerce for the Pharmaceutical Industry. Leveraging its advantages of full industrial chain coverage, broad representation, and high participation, the chamber convenes authoritative industry experts to form a data analysis team. Adhering to the principles of open data collection, objective analysis, and strict screening, the team systematically compiles data from various pharmaceutical sub-sectors to produce authoritative reports. This statistical activity has been conducted for eleven consecutive years, providing crucial data support for the development of China's pharmaceutical industry.

The selection criteria for the "2024-2025 Top 50 Pharmaceutical R&D Enterprises" comprehensively evaluate companies based on various dimensions, including business operations, translation of R&D achievements into results, innovation capability, and international development. This year's evaluation introduced new indicators such as the completeness of the corporate service chain and evaluations from upstream and downstream partners, aiming to set industry benchmarks and guide development direction.

Being selected for three consecutive years reflects the industry's high recognition of Caremo's professional, integrated, and quality-assured service system, signifying that its R&D capabilities and service standards now rank among the industry's forefront.

Looking ahead, Caremo will continue to strengthen innovation in its technology platforms, adhering to its corporate mission of "Dedicated to Health, Empowering Innovation." The company will collaborate with more ecosystem partners to build a highly efficient and synergistic pharmaceutical R&D system, promote coordinated development across the industrial chain, and inject more "Caremo Power" into the development of China's biopharmaceutical industry.